Understanding the role of plin5 in nonalcoholic fatty liver disease
the Role of plin5 in the Development of a Sequence Polymorphism in Patatin-like Phospholipid Domain Containing Protein 3 Polymorphism-associated Nonalcoholic Fatty Liver Disease
This study is trying to see how a specific protein in the liver is connected to nonalcoholic fatty liver disease and how it might help us find better ways to prevent and treat this condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT04104282 on ClinicalTrials.gov |
What this trial studies
This observational study aims to clarify the role of sequence polymorphism in the patatin-like phospholipid domain containing protein 3 and its association with nonalcoholic fatty liver disease (NAFLD). By analyzing human liver samples, the study will investigate the relationship between plin5 expression and the development of NAFLD linked to genetic variants. The research will also explore lipid metabolism and lipotoxicity in hepatocytes to better understand the mechanisms involved in NAFLD. The findings could provide insights into prevention and therapeutic strategies for this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with simple fatty liver disease without a history of alcohol consumption or other metabolic diseases.
Not a fit: Patients with long-term alcohol consumption, viral hepatitis, obesity, type 2 diabetes, or other metabolic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of nonalcoholic fatty liver disease.
How similar studies have performed: While the specific approach of this study may be novel, previous studies have indicated a significant association between genetic factors and nonalcoholic fatty liver disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: The diagnosis of simple fatty liver disease was confirmed by clinical presentation, ultrasound, and without long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases. Exclusion criteria: With long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases.
Where this trial is running
Xi'an, Shaanxi
- The Department of Ultrasonic Medicine, The Xijing Hospital of Fourth Military Medical University — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Study coordinator: Ming Yu, PhD, MD
- Email: huihui2807201830@163.com
- Phone: 15209239680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.